Keros Therapeutics (NASDAQ:KROS) Stock Price Down 8.9% – Time to Sell?

Keros Therapeutics, Inc. (NASDAQ:KROS) was down 8.9% on Monday . The company traded as low as $13.07 and last traded at $13.26. Approximately 220,614 shares were traded during trading, a decline of 72% from the average daily volume of 795,165 shares. The stock had previously closed at $14.56.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KROS. Oppenheimer decreased their target price on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, December 16th. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, December 16th. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. TD Cowen lowered Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Stock Performance

The firm’s fifty day moving average is $39.77 and its two-hundred day moving average is $47.88. The company has a market cap of $505.53 million, a P/E ratio of -2.40 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the business posted ($1.33) earnings per share. On average, equities research analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KROS. FMR LLC boosted its position in shares of Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC lifted its stake in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. lifted its stake in Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP grew its position in shares of Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.